Market Overview:

Enrofloxacin is a fluoroquinolone class antibiotic that treats certain types of bacterial infections in humans and animals. It is primarily used to treat respiratory infections and other bacterial infections in poultry and other livestock. It can be administered through injectables or orally via drinking water. Enrofloxacin offers broad spectrum activity against both gram-positive and gram-negative bacteria making it an effective therapeutic option for veterinary use.

Key Takeaways

The Global Enrofloxacin Market Size  is expected to witness high growth, exhibiting CAGR of 4.1% over the forecast period, due to increasing prevalence of zoonotic diseases and rising meat consumption worldwide.

Regional analysis

Asia Pacific dominates the global market and is projected to grow at the fastest rate owing to rising livestock farming, growing aquaculture industry and increase in per capita animal healthcare expenditure in countries such as India and China. North America is another major regional market for enrofloxacin driven by stringent food safety regulations and advanced animal healthcare practices.

Key players

Key players operating in the enrofloxacin market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd.

For more insights, read-  https://medium.com/@leena.cmi01/the-enrofloxacin-market-is-witnessing-high-growth-owing-to-increasing-demand-for-veterinary-bc2a3afbcfa8